Shineco, Inc. (SISI)
USD 0.87
(3.58%)
USD 0.87
(3.58%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 | 29.65 Million USD | 79.76% |
| 2023 | 16.49 Million USD | 0.58% |
| 2022 | 16.4 Million USD | 340.9% |
| 2021 | 3.72 Million USD | 31.3% |
| 2020 | 2.83 Million USD | 17.56% |
| 2019 | 2.41 Million USD | 4.05% |
| 2018 | 2.31 Million USD | -13.04% |
| 2017 | 2.66 Million USD | -3.0% |
| 2016 | 2.74 Million USD | -18.88% |
| 2015 | 3.38 Million USD | 26.72% |
| 2014 | 2.67 Million USD | -33.27% |
| 2013 | 4 Million USD | 0.0% |
| 2006 | 314 Thousand USD | 0.0% |
| 2005 | 314 Thousand USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q4 | 29.65 Million USD | -1.46% |
| 2024 Q3 | 30.09 Million USD | -3.49% |
| 2024 Q2 | 31.18 Million USD | 4.81% |
| 2024 Q1 | 29.75 Million USD | 80.35% |
| 2023 Q2 | 15.51 Million USD | -1.42% |
| 2023 Q4 | 16.49 Million USD | -3.85% |
| 2023 Q3 | 17.15 Million USD | 10.57% |
| 2023 FY | 16.49 Million USD | 0.58% |
| 2023 Q1 | 15.74 Million USD | 9.2% |
| 2022 Q3 | 16.46 Million USD | -6.94% |
| 2022 Q1 | 19.24 Million USD | 417.36% |
| 2022 FY | 16.4 Million USD | 340.9% |
| 2022 Q2 | 17.69 Million USD | -8.09% |
| 2022 Q4 | 14.41 Million USD | -12.43% |
| 2021 Q2 | 2.38 Million USD | -19.07% |
| 2021 Q3 | 2.37 Million USD | -0.23% |
| 2021 FY | 3.72 Million USD | 31.3% |
| 2021 Q4 | 3.72 Million USD | 56.51% |
| 2021 Q1 | 2.94 Million USD | 3.89% |
| 2020 FY | 2.83 Million USD | 17.56% |
| 2020 Q3 | 2.7 Million USD | 26.56% |
| 2020 Q4 | 2.83 Million USD | 4.79% |
| 2020 Q1 | 2.74 Million USD | 13.83% |
| 2020 Q2 | 2.13 Million USD | -22.12% |
| 2019 Q1 | 2.23 Million USD | -3.46% |
| 2019 Q2 | 2.14 Million USD | -4.18% |
| 2019 Q3 | 2.47 Million USD | 15.61% |
| 2019 Q4 | 2.41 Million USD | -2.71% |
| 2019 FY | 2.41 Million USD | 4.05% |
| 2018 Q2 | 1.2 Million USD | -46.59% |
| 2018 Q3 | 2.48 Million USD | 106.12% |
| 2018 Q4 | 2.31 Million USD | -6.65% |
| 2018 FY | 2.31 Million USD | -13.04% |
| 2018 Q1 | 2.25 Million USD | -15.38% |
| 2017 FY | 2.66 Million USD | -3.0% |
| 2017 Q4 | 2.66 Million USD | -8.7% |
| 2017 Q3 | 2.91 Million USD | 0.53% |
| 2017 Q2 | 2.9 Million USD | 6.3% |
| 2017 Q1 | 2.73 Million USD | -0.58% |
| 2016 Q4 | 2.74 Million USD | 8.98% |
| 2016 Q3 | 2.51 Million USD | -9.16% |
| 2016 Q2 | 2.77 Million USD | -11.74% |
| 2016 Q1 | 3.14 Million USD | -7.16% |
| 2016 FY | 2.74 Million USD | -18.88% |
| 2015 Q2 | 3.39 Million USD | 0.0% |
| 2015 Q4 | 3.38 Million USD | -4.0% |
| 2015 Q3 | 3.52 Million USD | 3.9% |
| 2015 Q1 | - USD | -100.0% |
| 2015 FY | 3.38 Million USD | 26.72% |
| 2014 Q3 | 8.36 Million USD | 0.0% |
| 2014 Q1 | - USD | -100.0% |
| 2014 FY | 2.67 Million USD | -33.27% |
| 2014 Q4 | 2.67 Million USD | -68.08% |
| 2013 FY | 4 Million USD | 0.0% |
| 2013 Q4 | 4.37 Million USD | 0.0% |
| 2007 Q2 | 822.56 Thousand USD | 161.96% |
| 2007 Q3 | - USD | -100.0% |
| 2007 Q1 | 314 Thousand USD | 0.0% |
| 2006 FY | 314 Thousand USD | 0.0% |
| 2006 Q3 | 663.55 Thousand USD | 0.0% |
| 2006 Q1 | - USD | 0.0% |
| 2005 FY | 314 Thousand USD | 0.0% |
| 2005 Q3 | - USD | -100.0% |
| 2005 Q2 | 314 Thousand USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 674.28 Million USD | 95.602% |
| Embecta Corp. | 1.63 Billion USD | 98.19% |
| ANI Pharmaceuticals, Inc. | 315.32 Million USD | 90.595% |
| Dynavax Technologies Corporation | 256.91 Million USD | 88.457% |
| Esperion Therapeutics, Inc. | 540.94 Million USD | 94.518% |
| Pacira BioSciences, Inc. | 586.04 Million USD | 94.94% |
| PainReform Ltd. | 86 Thousand USD | -34384.237% |
| Aquestive Therapeutics, Inc. | 98.82 Million USD | 69.99% |
| Sunshine Biopharma, Inc. | 657.7 Thousand USD | -4409.08% |
| SCYNEXIS, Inc. | 15.08 Million USD | -96.661% |
| China SXT Pharmaceuticals, Inc. | 2.64 Million USD | -1020.187% |
| Cosmos Health Inc. | 12.42 Million USD | -138.704% |
| Journey Medical Corporation | 17.73 Million USD | -67.267% |
| Sunshine Biopharma, Inc. | 657.7 Thousand USD | -4409.08% |
| Safety Shot Inc | 1.54 Million USD | -1814.586% |
| Alpha Teknova, Inc. | 30.45 Million USD | 2.632% |
| Intra-Cellular Therapies, Inc. | 16.93 Million USD | -75.088% |
| Bright Green Corporation | 1.85 Million USD | -1501.508% |
| Procaps Group, S.A. | 285.93 Million USD | 89.628% |
| Theratechnologies Inc. | 58.96 Million USD | 49.708% |
| Harrow Health, Inc. | 190.5 Million USD | 84.432% |
| Sonoma Pharmaceuticals, Inc. | 608 Thousand USD | -4777.705% |
| Biofrontera Inc. | 5.39 Million USD | -449.295% |
| DURECT Corporation | 20.74 Million USD | -42.95% |
| Supernus Pharmaceuticals, Inc. | 41.52 Million USD | 28.585% |
| Cronos Group Inc. | 2.53 Million USD | -1067.605% |
| OptiNose, Inc. | 131.74 Million USD | 77.49% |
| Ironwood Pharmaceuticals, Inc. | 715.53 Million USD | 95.855% |
| Kala Pharmaceuticals, Inc. | 36.32 Million USD | 18.354% |
| RedHill Biopharma Ltd. | 1.17 Million USD | -2428.243% |
| Organogenesis Holdings Inc. | 119.35 Million USD | 75.152% |
| Guardion Health Sciences, Inc. | - USD | -Infinity% |
| Cumberland Pharmaceuticals Inc. | 18.42 Million USD | -60.927% |
| Radius Health, Inc. | 365.31 Million USD | 91.882% |
| Universe Pharmaceuticals INC | 5.48 Million USD | -440.934% |
| ProPhase Labs, Inc. | 21.38 Million USD | -38.711% |
| Phibro Animal Health Corporation | 525.45 Million USD | 94.356% |
| Procaps Group S.A. | 285.93 Million USD | 89.628% |
| Alvotech | 1.07 Billion USD | 97.242% |
| TherapeuticsMD, Inc. | 8 Million USD | -270.474% |
| Viatris Inc. | 18.12 Billion USD | 99.836% |
| Rockwell Medical, Inc. | 13.43 Million USD | -120.674% |
| Aytu BioPharma, Inc. | 15.12 Million USD | -96.024% |
| SIGA Technologies, Inc. | 1.46 Million USD | -1925.701% |
| Tilray Brands, Inc. | 387.31 Million USD | 92.343% |
| Lifecore Biomedical, Inc. | 130.36 Million USD | 77.25% |
| PetIQ, Inc. | 468.3 Million USD | 93.667% |
| Regencell Bioscience Holdings Limited | 59.8 Thousand USD | -49486.911% |
| Incannex Healthcare Limited | 373 Thousand USD | -7850.789% |
| Neurocrine Biosciences, Inc. | 428.4 Million USD | 93.077% |
| Alimera Sciences, Inc. | 67.39 Million USD | 55.999% |
| Silver Spike Investment Corp. | - USD | -Infinity% |
| Assertio Holdings, Inc. | 40.91 Million USD | 27.512% |
| Shuttle Pharmaceuticals Holdings, Inc. | 1.08 Million USD | -2626.543% |
| Petros Pharmaceuticals, Inc. | 8.27 Million USD | -258.317% |
| Clever Leaves Holdings Inc. | 2.08 Million USD | -1321.008% |
| Cyclo Therapeutics, Inc. | 1.03 Million USD | -2770.585% |
| Avadel Pharmaceuticals plc | 35.38 Million USD | 16.187% |
| Hempacco Co., Inc. | 13.72 Million USD | -116.084% |
| Talphera, Inc. | - USD | -Infinity% |
| Alvotech | 1.07 Billion USD | 97.242% |
| Eagle Pharmaceuticals, Inc. | 62.46 Million USD | 52.524% |
| Lantheus Holdings, Inc. | 616.94 Million USD | 95.193% |
| Currenc Group, Inc. | 31.94 Million USD | 7.16% |
| Kamada Ltd. | 8.74 Million USD | -238.97% |
| Indivior PLC | 281.6 Million USD | 89.469% |
| Evoke Pharma, Inc. | 5 Million USD | -493.129% |
| Flora Growth Corp. | 3.67 Million USD | -707.637% |
| Cyclo Therapeutics, Inc. | 1.03 Million USD | -2770.585% |
| Evolus, Inc. | 126.54 Million USD | 76.565% |
| HUTCHMED (China) Limited | 86.13 Million USD | 65.568% |
| Amphastar Pharmaceuticals, Inc. | 623.64 Million USD | 95.245% |
| Akanda Corp. | 3.99 Million USD | -641.635% |